Key Points
- Director Corey Michael Watton sold 12,300 Zevra shares at an average price of $11.25, generating $138,375. Following the transaction, his direct ownership fell 87.23% to 1,800 shares.
- Zevra reported a quarterly EPS of $0.25, beating the $0.11 analyst consensus, while revenue of $39.66 million exceeded estimates of $33.88 million.
- Analyst sentiment remains positive, with nine Buy ratings and two Holds, producing a “Moderate Buy” consensus and an average price target of $27.14 versus the stock’s reported $11.44 price.
Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) Director Corey Michael Watton sold 12,300 shares of the company's stock in a transaction on Monday, August 10th. The shares were sold at an average price of $11.25, for a total transaction of $138,375.00. Following the completion of the sale, the director directly owned 1,800 shares in the company, valued at $20,250. This trade represents a 87.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Zevra Therapeutics Price Performance
NASDAQ:ZVRA opened at $11.44 on Thursday. The company's fifty day moving average price is $12.34 and its 200-day moving average price is $10.64. Zevra Therapeutics, Inc. has a 1-year low of $7.16 and a 1-year high of $15.03. The firm has a market capitalization of $679.31 million, a P/E ratio of 12.43 and a beta of 0.91.
Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported $0.25 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.11 by $0.14. Zevra Therapeutics had a net margin of 42.82% and a return on equity of 54.54%. The company had revenue of $39.66 million during the quarter, compared to the consensus estimate of $33.88 million. Equities analysts anticipate that Zevra Therapeutics, Inc. will post 0.6 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in ZVRA. AIGH Capital Management LLC purchased a new stake in shares of Zevra Therapeutics during the first quarter worth $11,184,000. Marshall Wace LLP purchased a new position in shares of Zevra Therapeutics in the third quarter worth about $8,676,000. Rubric Capital Management LP boosted its position in Zevra Therapeutics by 60.8% during the second quarter. Rubric Capital Management LP now owns 1,958,318 shares of the company's stock worth $17,253,000 after acquiring an additional 740,584 shares during the last quarter. Adage Capital Partners GP L.L.C. boosted its position in Zevra Therapeutics by 15.2% during the second quarter. Adage Capital Partners GP L.L.C. now owns 4,168,000 shares of the company's stock worth $36,720,000 after acquiring an additional 550,000 shares during the last quarter. Finally, Nantahala Capital Management LLC boosted its position in Zevra Therapeutics by 34.0% during the third quarter. Nantahala Capital Management LLC now owns 1,971,936 shares of the company's stock worth $18,753,000 after acquiring an additional 500,000 shares during the last quarter. 35.03% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several equities analysts have recently issued reports on ZVRA shares. Citigroup reissued an "outperform" rating on shares of Zevra Therapeutics in a report on Thursday, August 6th. Guggenheim dropped their target price on Zevra Therapeutics from $24.00 to $23.00 and set a "buy" rating on the stock in a report on Friday, August 7th. HC Wainwright reiterated a "buy" rating and set a $26.00 price target on shares of Zevra Therapeutics in a research report on Tuesday, June 23rd. Wall Street Zen raised Zevra Therapeutics from a "hold" rating to a "buy" rating in a report on Sunday, July 12th. Finally, Canaccord Genuity Group lowered their price objective on Zevra Therapeutics from $29.00 to $20.00 and set a "buy" rating on the stock in a research report on Monday, July 27th. Nine investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $27.14.
Get Our Latest Stock Analysis on Zevra Therapeutics
Zevra Therapeutics Company Profile
(
Get Free Report)
Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
